がん検診
早期がん発見の実証されたアプリケーション
がん検診
GASTROClear
世界初胃がん早期発見のためのマイクロRNA血液検査
- 初期の胃がんを見つけます
- 現在シンガポールでで販売中
- 承認済み－シンガポールヘルスサイエンス庁から体外診断用医薬品承認済み，CEマーク、ISO13485の認証を取得しております。
- 初期の胃がんを見つけます(ステージ0～2)高精度で
Video
Interview with Professor Yeoh Khay Guan, Lead Principal Investigator of the Singapore Gastric Cancer Consortium
Play Video
Media Coverage
Diagnostic solutions for infectious, cardiovascular, and metabolic diseases
Fortitude Kit
新型コロナウイルス（SARS-CoV-2）PCR検査法
- First COVID-19 diagnostic test kit approved for use in Singapore through Provisional Authorization by Singapore's Health Sciences Authority(HSA).
- Deployed in 13 Singapore hospitals and labs and over 30 countries worldwide since February 2020. Exported to USA, Hong Kong, New Zealand, and Panama, among others.
- Can be combined with MiRXES Swab Collection System and MAGec automated RNA extraction solution for a complete end-to-end COVID-19 testing solution.
- Developed by researchers at Singapore's Agency for Science, Technology and Research (A*STAR) and Tan Tock Seng Hospital (TTSH). Technology has been licensed to MiRXES in February 2020 for mass production.
- MiRXES is a legal product owner of Fortitude Kit since March 2020.
Technical details
- A 1-step real-time RT-PCR test for detecting SARS-CoV-2 virus.
- Targets the portion of the virus genome that is less prone to mutation, enabling robust detection of the virus.
- Analytical Limit of Detection (LoD): 10 copies per reaction.
- Time from RNA to result: 90-120 minutes.
- Compatible with Bio-Rad, Applied Biosystems, and Roche real-time PCR equipment.
Video
Interview with Dr Zhou Lihan, CEO of MiRXES
Play Video
Media Coverage
Explainer Video: microRNA biomarkers for disease detection
Play Video